Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference25 articles.
1. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1;Graf;Neurol. Neuroimmunol. Neuroinflamm.,2021
2. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen;Wang;MAbs,2020
3. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX;Pawluczkowycz;J. Immunol.,2009
4. Rituximab for the treatment of multiple sclerosis: a review;Chisari;J. Neurol.,2022
5. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells;Lindorfer;Mol. Immunol.,2016
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The complement system as a target in cancer immunotherapy;European Journal of Immunology;2024-07-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3